Genetic Signatures (ASX:GSS) - Stock Price, News & Analysis

GSS Stock Overview

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. More details

GSS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 84% below our estimate of its fair value

Earnings are forecast to grow 98.62% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Genetic Signatures Limited Competitors

Proteomics International Laboratories

ASX:PIQ

AU$89.1m

Trajan Group Holdings

ASX:TRJ

AU$155.3m

EZZ Life Science Holdings

ASX:EZZ

AU$127.5m

Cryosite

ASX:CTE

AU$43.0m

Price History & Performance

Summary of all time highs, changes and price drops for Genetic Signatures
Historical stock prices
Current Share Price	AU$0.72
52 Week High	AU$0.85
52 Week Low	AU$0.38
Beta	0.054
11 Month Change	12.11%
3 Month Change	1.06%
1 Year Change	44.95%
33 Year Change	-42.37%
5 Year Change	-34.77%
Change since IPO	47.94%

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

Shareholder Returns

	GSS	AU Life Sciences	AU Market
7D	0.3%	-6.0%	1.5%
1Y	44.9%	11.8%	17.2%

Return vs Industry: GSS exceeded the Australian Life Sciences industry which returned 11.8% over the past year.

Return vs Market: GSS exceeded the Australian Market which returned 17.2% over the past year.

Price Volatility

Is GSS's price volatile compared to industry and market?
GSS volatility
GSS Average Weekly Movement	6.6%
Life Sciences Industry Average Movement	11.2%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: GSS has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: GSS's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2001	n/a	Allison Rossiter	www.geneticsignatures.com

Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, SARS-CoV-2 respiratory plus, coronavirus, atypical respiratory, pertussis and PCP, parainfluenza 4, STI genital pathogen, extended spectrum beta-lactamase and carbapenemase producing organisms, viral meningitis, flavivirus dengue alphavirus, flavivirus reflex, dengue typing, and alphavirus reflex Detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.

Genetic Signatures Limited Fundamentals Summary

How do Genetic Signatures's earnings and revenue compare to its market cap?
GSS fundamental statistics
Market cap	AU$158.81m
Earnings (TTM)	-AU$17.86m
Revenue (TTM)	AU$13.77m

11.8x

P/S Ratio

-9.1x

P/E Ratio

Is GSS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GSS income statement (TTM)
Revenue	AU$13.77m
Cost of Revenue	AU$7.91m
Gross Profit	AU$5.86m
Other Expenses	AU$23.72m
Earnings	-AU$17.86m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.079
Gross Margin	42.53%
Net Profit Margin	-129.74%
Debt/Equity Ratio	0%

How did GSS perform over the long term?

See historical performance and comparison

GSS Stock Overview

Rewards

Risk Analysis

Genetic Signatures Limited Competitors

ASX:PIQ

AU$89.1m

ASX:TRJ

AU$155.3m

ASX:EZZ

AU$127.5m

ASX:CTE

AU$43.0m

Price History & Performance

Recent News & Updates

Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Recent updates

Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

Shareholder Returns